IXI.L Stock Analysis
IX
Uncovered
IXICO PLC is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
IXICO Plc engages in the provision of technology-enabled specialty services to the global biopharmaceutical industry. The firm is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The firm's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. The company has developed and deployed data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients. Its services include trial design and consultation, project management, imaging site set-up and management, data management and others.